Corcept Therapeutics (CORT) Finished Goods (2012 - 2026)
Corcept Therapeutics (CORT) posted Finished Goods of $13.2 million for Q2 2026, down 9.97% sequentially from $14.7 million in Q1 2026, and up 96.73% YoY from $6.7 million in Q2 2025.
Corcept Therapeutics (CORT) Finished Goods (2012 - 2026) Analysis & Trends
Corcept Therapeutics has reported Finished Goods for 15 years, with the latest figure at $13.2 million in Q2 2026.
- Quarterly Finished Goods rose 96.73% year-over-year to $13.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $13.2 million (up 96.73% YoY) and the FY2025 annual result came in at $9.4 million, up 14.7% from the prior year.
- Finished Goods fell to $13.2 million in Q2 2026 per CORT's latest filing, from $14.7 million in the prior quarter.
- Over five years, Finished Goods peaked at $14.7 million in Q1 2026 and troughed at $5.5 million in Q1 2022.
- A 5-year average of $8.4 million and a median of $8.1 million in 2023 frame the typical range for Finished Goods.
- The sharpest annual moves came in 2025 and 2026: Finished Goods slipped 19.47% in 2025, then surged 96.73% in 2026.
- Over 5 years, Finished Goods stood at $9.2 million in 2022, then dropped by 15.9% to $7.7 million in 2023, then grew by 6.01% to $8.2 million in 2024, then rose by 14.7% to $9.4 million in 2025, then jumped by 40.54% to $13.2 million in 2026.
- According to Business Quant data, Finished Goods over the past three periods registered $13.2 million, $14.7 million, and $9.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.23 Mn |
| Mar 31, 2026 | 14.69 Mn |
| Dec 31, 2025 | 9.41 Mn |
| Sep 30, 2025 | 8.60 Mn |
| Jun 30, 2025 | 6.72 Mn |
| Mar 31, 2025 | 8.50 Mn |
| Dec 31, 2024 | 8.21 Mn |
| Sep 30, 2024 | 8.05 Mn |
| Jun 30, 2024 | 8.35 Mn |
| Mar 31, 2024 | 7.20 Mn |
| Dec 31, 2023 | 7.74 Mn |
| Sep 30, 2023 | 7.52 Mn |
| Jun 30, 2023 | 9.00 Mn |
| Mar 31, 2023 | 8.05 Mn |
| Dec 31, 2022 | 9.20 Mn |
| Sep 30, 2022 | 5.90 Mn |
| Jun 30, 2022 | 6.04 Mn |
| Mar 31, 2022 | 5.54 Mn |
| Dec 31, 2021 | 6.50 Mn |
| Sep 30, 2021 | 4.93 Mn |